AstraZeneca drug clears hurdle

AstraZeneca said yesterday that it had moved one step closer to being able to market a new drug to help ovarian cancer patients. The FTSE 100 pharmaceuticals giant said that the European Medicines Agency had accepted its Marketing Authorisation Application (MAA) for olaparib. A spokesperson for the firm said it hopes to hear whether it has been given the go-ahead by the European regulator in the coming months.